Revisão de literatura: Síndrome de Guillain-Barré e Polineuropatia desmielinizante inflamatória crônica / Literature review: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
DOI:
https://doi.org/10.34119/bjhrv3n2-115Keywords:
Polineuropatia ¹. diagnóstico diferencial ². Síndrome de Guillain-Barré ³. Polirradiculoneuropatia Desmielinizante Inflamatória Crônica ?.Abstract
Revisão de literatura sobre as Síndromes de Guillain-Barré e Polineuropatia desmielinizante inflamatória crônica. Nesse estudo, os bancos de dados para a pesquisa foram: Scielo, PubMed, MedLine e LILACS. As palavras chaves “Polineuropatia”, “Síndrome de Guillain-Barré” e” Polirradiculoneuropatia Desmielinizante Inflamatória Crônica” foram escolhidas e os artigos selecionados sem definição de datas ou restrição de publicação. Excluindo a duração da evolução, o quadro agudo e formas crônicas são semelhantes em muitos aspectos. Ambos são polirradiculoneuropatias generalizadas, geralmente com citoalbuminologia e dissociação do líquido cefalorraquidiano; ambos nervos exibem anormalidades de condução características de uma neuropatia desmielinizante (redução da velocidade de condução e bloqueio de condução em nervos motores), e patologicamente, ambas mostram inflamação perivenosa multifocal semelhante a infiltrados. Porém, existem diferenças importantes, as mais evidentes são os modos de evolução, respostas ao tratamento e prognóstico. A polineuropatia desmielinizante inflamatória crônica é uma doença comum, embora subdiagnosticada e potencialmente tratável, com prevalência de cerca de 0,5 por 100.000 crianças e 1 a 2 por 100.000 adultos. Semelhanças clínicas com a variante aguda da polineuropatia desmielinizante inflamatória (síndrome de Guillain-Barré) e os efeitos benéficos da imunossupressão terapia sugerem uma patogênese imunomediada. Desde as primeiras descrições de pacientes com polineuropatias crônicas responsivas a corticosteroides por Austin,o espectro da apresentação clínica e do arsenal de diagnóstico aumentaram e outras opções terapêuticas evoluíramReferences
Adina R. Alport, MD; Howard W. Sander, MD Clinical Approach to Peripheral Neuropathy: Anatomic Localization and Diagnostic Testing American Academy of Neurology: Continuum Lifelong Learning Neurol 2012;18(1):13–38
Asbury AK, Arnason BG, Adams RD (1969): The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis medicine 48: 173-215.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:Suppl:S21-S24.
Aymeé Hernández Hernández. CIDP: Clinical and electrophysiological aspects. Acta Neurol Colomb 2011;28:202-212.
Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498–503
BRANNAGAN TH. High dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurol¬ogy. 2002; 58:1856-8.
BURNS TM. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2004; 61:973-5.
Charcot J, Marie P. Sue une forme particulaire d’atrophie musculaire progressive souvent familial debutant par lês pieds et lês jamber et atteingnant plus tard lês mains. Rev Med 1886;6:97.
Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic demyelinating inflammatory polyradiculoneuropathy. Eur J Neurol. 2009.
Connolly AM. Chronic inflammatory demyelinating polyneuropathy in childhood. Pediatr Neurol 2001;24:177-82.
Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9: Suppl:134-45.
Dourado ME, Félix RH, da Silva WK, Queiroz JW, Jeronimo SM. Clinical characteristics of Guillain-Barré syndrome in a tropical country: a Brazilian experience. Acta Neurol Scand. 2012;125(1):47-53.
Dyck, P.J. and Arnason, B.G.W. (1984) Chronic Inflammatory demyelinating polyradiculoneuropathy. In: P.J. Dyck, P.K. Thomas, E.H. Lambert and R. Bunge (Eds.), Peripheral Neuropathy. W.B. Saunders, Philadelphia, PA, pp. 2101-2114.
DYCK PJ, THOMAS PK. Peripheral Neuropathy. 3 Ed. New York. WB Saunders. 1993; 2: 1298-1524
England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72(2):185Y192.
Evandro Penteado Villar Félix, Acary de Souza Bulle Oliveira. Diretrizes para abordagem diagnóstica das neuropatias em serviço de referência em doenças neuromusculares. Rev Neurocienc 2010
GORSON KC. High dose immunosuppresion for refractory CIDP? J. Neurology. 2002; 22: 25-8
Guillain G, Barré JA, Strohl A. Sur um syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des reflexes tendineux. Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris 1916;40:1462-70.
GUTIÉRREZ RIVAS E, JIMÉNEZ MD, PARDO J, ROMER J, EDS. Manual de Electromiografía Clínica. Barcelona España: Prus Science. 2000.
GUTIÉRREZ RIVAS E, JIMÉNEZ MD, PARDO J, ROMER J, EDS. Manual de Electromiografía Clínica. Barcelona España: Prus Science. 2000
Hadden RDM, Karch H, Hartung HP,et al. Preceding infections, immune factors,and out come in Guillain-Barré syndrome.Neurology 2001;56:758-65.
Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39:625-35.
Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352(9128):635-41
Hartung, H.P., Stoll, G. and Toyka, K.V. (1993). Immune Reactions in the peripheral nervous system. In: P.J. Dyck, P.K. Thomas (Eds.). Peripheral Neuropathy. W.B. Saunders, phipadelphia, PA, pp. 418-454.
Haldeman D, Zulkosky K. Treatment and nursing care for a patient with Guillain-Barré syndrome. Dimens Crit Care Nurs 2005;24:267-72.
Honavar, M., Tharakan, J.K.J., Hughes, R.A.C., Leibowiz, S. and Winer, J.B. (1991) A clinicopathological study of the Guillain-Barré syndrome. Brain 114, 1245-1269.
Hubertus Koller, M.D., Bernd C. Kieseier, M.D., Sebastian Jander, M.D., and Hans-Peter Hartung, M.D. Chronic Inflammatory Demyelinating Polyneuropathy N Engl J Med 2005;352:1343-56.
Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194-8.
Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-66.
Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245-57.
Hughes RAC, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62:1194-8.
Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50: 195-201.
HUGHES RA. Systematic reviews of treatment for CIDP. Rev Neurol (Paris). 2002; 158 (12 Pt2): 32-6.
Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedente infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-5.
Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré syndrome following recente herpes zoster: a populationbased study across Taiwan. Clin Infect Dis 2010;51:525-30.
Khalili-Shirazi A, Hughes RA, Brostoff SW, Linington C, Gregson N. T cell responses to myelin proteins in Guillain-Barre syndrome. J Neurol Sci. 1992;111:200–203
Kieseier BC, Hartung HP. Therapeutic strategies in the Guillain-Barré syndrome. Semin Neurol. 2003;23(2):159-68.
Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002;59: S7–S12.
Lunn MP, Manji H, Choudhary PP,Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England.
J Neurol Neurosurg Psychiatry 1999;66:677- 80.
McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-3.
Mohamed Mahdi-Rogers Yusuf A Rajabally. Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics: Targets & Therapy 2010
Nobuhiro Yuki, M.D., Ph.D., and Hans-Peter Hartung, M.D., Guillain–Barré Syndrome, N Engl J Med 2012;366:2294-304.
PASCUAL PASCUAL SL. Aspectos actuales de las neuropatías inflamatorias agudas y crónicas. Sindrome de Guillain-Barré y polineuritis crónica inflamatoria desmielinizante. Rev Neurol. 2002; 35:269-76.
Plasma Exchange/Sandoglobulin Guillain- Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30
Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr 2010;28:545 52.
Prineas, J.W. and McLeod, J.G. (1976) Chronic relapsing polyneuritis. J. Neurol. Sci. 27, 427-458.
Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci. 2009;16(6):733-41.
RADZIWILL AJ, KUNTZER T, STECK AJ. Immunopathology and treatments of Guillain Barre syndrome and chronic inflammatory demyelinating polirradiculoneuropathy. Rev Neurol (Paris). 2002; 158:301-10.
Reis RG, Oliveira ASB. Drogas e Sistema Nervoso Periférico. Rev Neurocinc 1999; 7:109
Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:617-8.
Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-6.
SANDOVAL P, ARAYA P. Inmunología en Neu¬rología. Cuadernos de Neurología. Vol XXIV, 2000.
Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain- Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-87
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33.
SERRADEL AP. Neuropatías disinmunes adquiri¬das. Sintomatología clínica y clasificación. Rev Neurol. 2000; 30:501-14.
Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ. Hereditary Motor and Sensory Neuropathies: An Overview of Clinical, Genetic, Electrophysiologic, and Pathologic Features. In: Dyck JP, Thomas PK (ed). Peripheral Neuropathy 4rd ed.Philadelphia: Elsevier Saunders, 2005, p.1623-58.
The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain- Barré syndrome. Neurology 1985;35: 1096-104.
Tooth H. The Peroneal Type of Progressive Muscular Atrophy. London: Lewis, 1886.
VALLAT JM, TABARAUD F, MAGY L, MACIAN F. Chronic polyrradiculoneuritis and its frontiers. Rev Neurol (Paris). 2002; 158: 27-31.
Vallat JM, Magy L. Neuropathies Périphériques: généralités. EMC. Neurologie 2005;2:175-81
Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
WALK D, LI LYJ, PARRY GJ, DAY JW. Rapid reso¬lution of quadriplegic CIDP by combined plasma¬pheresis and IVIg. Neurology. 2004; 62:155-6.
Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286–292.
